Table 2.
Treatment outcomes and toxicity of first-line chemotherapy
| SNUH, n (%) | KCCR, n (%) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total | Group 1 | Group 2 | P* | Total | Group 1 | Group 2 | P* | |
| Total patients | 131 | 106 | 23 | 1426 | 748 | 678 | ||
| Outcome | ||||||||
| CR | 76 (58.0) | 63 (59.4) | 12 (52.2) | .522 | NA | NA | NA | NA |
| 5-year survival | 21 (16.0) | 20 (18.9) | 1 (4.3) | .087 | 269 (18.9) | 166 (22.2) | 103 (15.2) | .549 |
| Death | ||||||||
| Early mortality | 15 (11.5) | 11 (10.4) | 3 (13.0) | .709 | 434 (33.4) | 272 (36.4) | 162 (23.9) | <.001 |
| Total mortality | 58 (44.3) | 45 (42.5) | 11 (47.8) | .637 | 908 (63.7) | 422 (56.4) | 486 (71.7) | <.001 |
| Toxicity | ||||||||
| Median (range) delay in chemotherapy, d | 27 (20.6) | 16 (15.1) | 11 (47.8) | <.001 | NA | NA | NA | NA |
| Anemia requiring transfusion | 23 (17.6) | 15 (14.2) | 7 (30.4) | .060 | 281 (19.7) | 133 (17.8) | 148 (21.8) | .0747 |
| Thrombocytopenia requiring transfusion | 13 (9.9) | 10 (9.4) | 3 (13.0) | .602 | 528 (37.0) | 275 (36.8) | 253 (37.3) | .9936 |
| Neutropenia requiring G-CSF | 41 (31.3) | 33 (31.1) | 8 (34.8) | .733 | NA | NA | NA | NA |
G-CSF, granulocyte colony-stimulating factor; NA, not available; SNUH, Seoul National University Hospital.
*
P values were calculated for group 1 vs group 2.